• IBA signed a sponsored research agreement with UT MD Anderson Cancer Center to strengthen health-economics evidence for proton beam therapy.
• Work targets cost-effectiveness across multiple cancer indications, weighing clinical outcomes, toxicity reduction, patient access, reimbursement, total cost of care.
• Projects will analyze direct, indirect costs from payer, patient, societal perspectives, including potential long-term economic benefits from reduced toxicity.
• Research will be led by Matthew Ning, MD, MPH, with Iakovos Toumazis, a decision analytics co-lead at MD Anderson’s oncology data science institute.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IBA - Ion Beam Applications SA published the original content used to generate this news brief on June 10, 2026, and is solely responsible for the information contained therein.